Scorr-Insert
X

Find Drugs for Infections and Infectious Diseases in Phase II/ Phase III Clinical Development

A collaboration with SCORR Marketing

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Country filter
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Sarilumab

            Therapeutic Area: Infections and Infectious Diseases

            Highest Development Status: Phase II/ Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 16, 2020

            Details:

            The US based trial will begin at medical centers in New York and will assess the safety and efficacy of adding Kevzara to usual supportive care, compared to supportive care plus placebo.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Ifenprodil Tartrate

            Therapeutic Area: Infections and Infectious Diseases

            Highest Development Status: Phase II/ Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 25, 2020

            Details:

            Algernon has submitted an Investigational New Drug application with the USFDA for its planned multinational Phase 2b/3 study of its re-purposed drug NP-120 as a potential therapeutic treatment for patients with COVID-19. Ifenprodil is an NMDA receptor antagonist.

            University of Oxford

            • Development Update

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): AZD1222

            Therapeutic Area: Infections and Infectious Diseases

            Highest Development Status: Phase II/ Phase III Product Type: Vaccine

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 22, 2020

            Details:

            Adult participants in both the Phase II and Phase III groups will be randomised to receive one or two doses of either the ChAdOx1 nCoV-19 vaccine or a licensed vaccine (MenACWY) that will be used as a ‘control’ for comparison.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Leronlimab

            Therapeutic Area: Infections and Infectious Diseases

            Highest Development Status: Phase II/ Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 21, 2020

            Details:

            The clinical trial to test whether leronlimab can prevent the "cytokine storm" that inflames and fatally damages the lungs and other organs of many COVID-19 patients.

            National Institutes of Health

            • Deals

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Leronlimab

            Therapeutic Area: Infections and Infectious Diseases

            Highest Development Status: Phase II/ Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: CytoDyn

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration May 20, 2020

            Details:

            CytoDyn will be coordinating with the NIH of Mexico and providing leronlimab for a trial for the severe/critical COVID-19 population in Mexico with the potential to collaborate on further CytoDyn COVID-19 trials.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Hydroxychloroquine Sulphate

            Therapeutic Area: Infections and Infectious Diseases

            Highest Development Status: Phase II/ Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Walter and Eliza Hall Institute of Medical Research

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration May 20, 2020

            Details:

            The COVID SHIELD clinical study will test an expanded indication for generic Hydroxychloroquine (HCQ) as a prophylactic treatment to prevent high-risk healthcare workers from contracting COVID-19.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Ifenprodil Tartrate

            Therapeutic Area: Infections and Infectious Diseases

            Highest Development Status: Phase II/ Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 18, 2020

            Details:

            Ifenprodil, an NDMA glutamate receptor antagonist exhibits agonist activity for the Sigma-1 receptor, a chaperone protein up-regulated during endoplasmic reticulum stress. Upon receiving all ethics approvals, the trial will begin as a Phase IIb study comprising 100 patients.

            UCI Health

            • Development Update

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Aviptadil

            Therapeutic Area: Infections and Infectious Diseases

            Highest Development Status: Phase II/ Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 14, 2020

            Details:

            In the current trial, which would be conducted by UCI Health, the drug will be employed in a Phase IIb/III clinical study of Covid-19 patients suffering from acute respiratory distress syndrome (ARDS), one of the primary causes of coronavirus-induced death.

            RDIF

            • Development Update

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Favipiravir

            Therapeutic Area: Infections and Infectious Diseases

            Highest Development Status: Phase II/ Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 13, 2020

            Details:

            Positive first interim results of the multicenter randomized open comparative clinical trial of the drug Favipiravir on patients hospitalized with COVID-19 were announced. 60% of the 40 patients who took Favipiravir have tested negative for Covid-19 after 5 days of treatment.

            National Center for Advancing Translational Sciences

            • Deals

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Emetine

            Therapeutic Area: Infections and Infectious Diseases

            Highest Development Status: Phase II/ Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Acer Therapeutics

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration May 11, 2020

            Details:

            Under the agreement, Acer and NCATS will collaborate to accelerate the clinical development of emetine, a broad-acting and potent antiviral according to various preclinical and clinical studies.

            PharmaCompass